Onvansertib continues to show dose-dependent activity in KRAS-mutated mCRC, with response rates improving up to 49% in the high-dose arm. Recent data are less dramatic than early interim results, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback